WHO ICTRP trial
Bioequivalence study of Capecitabine tablets 500 mg
CTRI/2018/05/014342 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2018/05/014342 |
|---|---|
| Public title | Bioequivalence study of Capecitabine tablets 500 mg |
| Scientific title | An open label, balanced, randomized, two treatment, three sequence, threeperiod, single dose, Semi replicate, cross over, bioequivalence study of Capecitabine tablets 500 mg of Mega Pharma S.A. Chile and Xeloda® (Capecitabine) tablets 500 mg of Roche in metastatic cancer patients under fed… |
| Primary sponsor | Mega Pharma SA |
| Secondary sponsors | Azidus Laboratories Limited |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | BA/BE |
| Countries | India |
| Conditions | Health Condition 1: null- Metastatic cancer patients |
| Interventions | Intervention1: Capecitabine tablets 500 m: Capecitabine tablets 500 mg of Mega Pharma S.A. Chile Control Intervention1: Xeloda®: Capecitabine tablets 500 mg of Roche |
| Registration date | May 31, 2018 |
| Target size | 42 |
| Secondary IDs | AZ/BE/04/17/11 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: